{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:41:11Z","timestamp":1765806071650,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FDA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Anthrax toxin is a critical virulence factor of Bacillus anthracis. The toxin comprises protective antigen (PA) and two enzymatic moieties, edema factor (EF) and lethal factor (LF), forming bipartite lethal toxin (LT) and edema toxin (ET). PA binds cellular surface receptors and is required for intracellular translocation of the enzymatic moieties. For this reason, anti-PA antibodies have been developed as therapeutics for prophylaxis and treatment of human anthrax infection. Assays described publicly for the control of anti-PA antibody potency quantify inhibition of LT-mediated cell death or the ET-induced increase in c-AMP levels. These assays do not fully reflect and\/or capture the pathological functions of anthrax toxin in humans. Herein, we report the development of a cell-based gene reporter potency assay for anti-PA antibodies based on the rapid LT-induced degradation of c-Jun protein, a pathogenic effect that occurs in human cells. This new assay was developed by transducing Hepa1c1c7 cells with an AP-1 reporter lentiviral construct and has been qualified for specificity, accuracy, repeatability, intermediate precision, and linearity. This assay not only serves as a bioassay for LT activity, but has applications for characterization and quality control of anti-PA therapeutic antibodies or other products that target the AP-1 signaling pathway.<\/jats:p>","DOI":"10.3390\/toxins15090528","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:46:47Z","timestamp":1693201607000},"page":"528","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics"],"prefix":"10.3390","volume":"15","author":[{"given":"Weiming","family":"Ouyang","sequence":"first","affiliation":[{"name":"Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Frucht","sequence":"additional","affiliation":[{"name":"Division of Biotechnology Review and Research II, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1164\/rccm.201102-0209CI","article-title":"Anthrax infection","volume":"184","author":"Sweeney","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-micro-091014-104523","article-title":"Anthrax Pathogenesis","volume":"69","author":"Moayeri","year":"2015","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bower, W.A., Hendricks, K.A., Vieira, A.R., Traxler, R.M., Weiner, Z., Lynfield, R., and Hoffmaster, A. (2022). What Is Anthrax?. Pathogens, 11.","DOI":"10.3390\/pathogens11060690"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Doganay, M., Dinc, G., Kutmanova, A., and Baillie, L. (2023). Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061056"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/cid\/ciac536","article-title":"Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880\u20132018","volume":"75","author":"Person","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","unstructured":"Williams, M., Armstrong, L., and Sizemore, D.C. (2023). StatPearls, StatPearls Publishing LLC."},{"key":"ref_8","first-page":"376","article-title":"Bioterrorism","volume":"104","author":"Rathjen","year":"2021","journal-title":"Am. Fam. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: Updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(02)07792-9","article-title":"Anthrax inhalation and lethal human infection","volume":"359","author":"Peters","year":"2002","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tim.2014.02.012","article-title":"Anthrax lethal and edema toxins in anthrax pathogenesis","volume":"22","author":"Liu","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183715","DOI":"10.1016\/j.bbamem.2021.183715","article-title":"Anthrax toxin channel: What we know based on over 30 years of research","volume":"1863","author":"Liu","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_14","unstructured":"(2018). Obiltoxaximab (Anthim) for inhalation anthrax. Med. Lett. Drugs Ther., 60, 150\u2013151."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4161\/mabs.1.6.10195","article-title":"Raxibacumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/bj3520739","article-title":"Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor","volume":"352","author":"Vitale","year":"2000","journal-title":"Biochem. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17919","DOI":"10.1074\/jbc.M117.805648","article-title":"Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation","volume":"292","author":"Ouyang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41564-020-0782-1","article-title":"Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality","volume":"5","author":"Mendenhall","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Levinsohn, J.L., Newman, Z.L., Hellmich, K.A., Fattah, R., Getz, M.A., Liu, S., Sastalla, I., Leppla, S.H., and Moayeri, M. (2012). Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002638"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chavarria-Smith, J., and Vance, R.E. (2013). Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003452"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Newman, Z.L., Printz, M.P., Liu, S., Crown, D., Breen, L., Miller-Randolph, S., Flodman, P., Leppla, S.H., and Moayeri, M. (2010). Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000906"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbrc.2010.07.039","article-title":"Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages","volume":"398","author":"Newman","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/20014091096738","article-title":"Anthrax toxin","volume":"27","author":"Bhatnagar","year":"2001","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.1980.tb18910.x","article-title":"Inhalation anthrax","volume":"353","author":"Brachman","year":"1980","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1093\/cid\/ciac532","article-title":"Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review","volume":"75","author":"Hesse","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/toxins3081004","article-title":"Monoclonal antibody therapies against anthrax","volume":"3","author":"Chen","year":"2011","journal-title":"Toxins"},{"key":"ref_28","unstructured":"(2013). Raxibacumab for anthrax. Med. Lett. Drugs Ther., 55, 27\u201328."},{"key":"ref_29","unstructured":"(2006). Drugs and Lactation Database, LactMed(R)."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/13543784.2010.489547","article-title":"Raxibacumab for inhalational anthrax: An effective specific therapeutic approach?","volume":"19","author":"Antoniu","year":"2010","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/IDR.S47305","article-title":"Raxibacumab: Potential role in the treatment of inhalational anthrax","volume":"7","author":"Kummerfeldt","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","article-title":"Obiltoxaximab: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cpdd.410","article-title":"Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans","volume":"7","author":"Nagy","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1177\/1060028017713029","article-title":"Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection","volume":"51","author":"Hou","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CVI.00513-09","article-title":"Comparison of three anthrax toxin neutralization assays","volume":"17","author":"Ngundi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jim.2004.12.022","article-title":"Development of an edema factor-mediated cAMP-induction bioassay for detecting antibody-mediated neutralization of anthrax protective antigen","volume":"298","author":"Zmuda","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1128\/CVI.00023-06","article-title":"Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays","volume":"13","author":"Mabry","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.toxicon.2008.08.011","article-title":"Ratio of lethal and edema factors in rabbit systemic anthrax","volume":"52","author":"Molin","year":"2008","journal-title":"Toxicon"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/infdis\/jix487","article-title":"Gastric pH and Toxin Factors Modulate Infectivity and Disease Progression After Gastrointestinal Exposure to Bacillus anthracis","volume":"216","author":"Xie","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0955-0674(97)80068-3","article-title":"AP-1 function and regulation","volume":"9","author":"Karin","year":"1997","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejcb.2013.10.003","article-title":"AP-1\/c-Jun transcription factors: Regulation and function in malignant melanoma","volume":"93","author":"Kappelmann","year":"2014","journal-title":"Eur. J. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s13238-011-1113-3","article-title":"c-Jun, at the crossroad of the signaling network","volume":"2","author":"Meng","year":"2011","journal-title":"Protein Cell"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ouyang, W., and Frucht, D.M. (2021). Erk1\/2 Inactivation-Induced c-Jun Degradation Is Regulated by Protein Phosphatases, UBE2d3, and the C-Terminus of c-Jun. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083889"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1073\/pnas.1913698117","article-title":"Erk1\/2 inactivation promotes a rapid redistribution of COP1 and degradation of COP1 substrates","volume":"117","author":"Ouyang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10529-022-03300-8","article-title":"High efficiency sorting and outgrowth for single-cell cloning of mammalian cell lines","volume":"44","author":"Munoz","year":"2022","journal-title":"Biotechnol. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Xie, T., Sun, C., Uslu, K., Auth, R.D., Fang, H., Ouyang, W., and Frucht, D.M. (2013). A New Murine Model for Gastrointestinal Anthrax Infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066943"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1128\/AAC.00458-13","article-title":"Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax","volume":"57","author":"Mytle","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Clark, A., and Wolfe, D.N. (2020). Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward. Microorganisms, 8.","DOI":"10.3390\/microorganisms8050651"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.4049\/jimmunol.174.8.4966","article-title":"Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells","volume":"174","author":"Fang","year":"2005","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.3390\/toxins7103960","article-title":"Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax","volume":"7","author":"Huang","year":"2015","journal-title":"Toxins"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/528\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:35Z","timestamp":1760128835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["toxins15090528"],"URL":"https:\/\/doi.org\/10.3390\/toxins15090528","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}